Artelo Biosciences Announces New Data On ART26.12 Demonstrating Effects In Multiple Models Of Neuropathic Pain At The 33rd Annual International Cannabinoid Research Society Symposium
Portfolio Pulse from Happy Mohamed
Artelo Biosciences announced new data on ART26.12, a FABP5 inhibitor, showing positive effects in multiple models of neuropathic pain. The global neuropathic pain market is valued at $7.6 billion in 2023. Artelo anticipates FDA pre-IND meeting minutes during Q3 2023.
June 27, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Artelo Biosciences' ART26.12 shows positive effects in neuropathic pain models, targeting a $7.6 billion market. FDA pre-IND meeting minutes expected in Q3 2023.
The positive data on ART26.12 indicates potential for Artelo Biosciences to enter the neuropathic pain market, valued at $7.6 billion. The anticipated FDA pre-IND meeting minutes in Q3 2023 could further advance the development of ART26.12, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100